Literature DB >> 24911669

Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action.

Jay M Margolis1, Bong-Chul Chu2, Zhixiao J Wang3, Ronda Copher4, Jose E Cavazos5.   

Abstract

IMPORTANCE: To our knowledge, the current study is the first to describe antiepileptic drug (AED) combination therapy patterns according to their mechanism of action (MOA) in a real-world setting and to evaluate the differences in outcomes comparing different-MOA combination therapy with same-MOA combination therapy for patients with partial-onset seizure.
OBJECTIVE: To compare treatment persistence and health care use with AED combinations categorized by MOA in patients with partial-onset seizures. DESIGN, SETTING, AND PARTICIPANTS: Using the Truven Health MarketScan Commercial Claims Database containing 96 million covered lives from July 1, 2004, through March 31, 2011, adults with concomitant use of 2 different AEDs and a recent partial-onset seizure diagnosis were selected. Antiepileptic drugs were categorized by MOA: sodium channel blockers (SC), gamma-aminobutyric acid analogs (G), synaptic vesicle protein 2A binding (SV2), and multiple mechanisms (M). Patients were assigned a combination category based on their concomitant AED use. MAIN OUTCOMES AND MEASURES: Treatment persistence was measured from the start of AED combination therapy until the end of the combination. Health care resource use was measured during the combination treatment duration. Multivariate analyses evaluated AED discontinuation risk and health care use according to MOA combinations.
RESULTS: Distribution of 8615 selected patients by combination was 3.3% for G+G, 7.5% for G+SV2, 8.6% for G+M, 13.9% for SC+SC, 19.0% for G+SC, 21.5% for SC+M, and 26.3% for SC+SV2. The same-MOA (G+G and SC+SC) combinations had the shortest persistence (mean [SD], 344 [345] days and 513 [530] days, respectively) and greater hazard of discontinuation compared with different-MOA combinations. Patients with different-MOA G combinations had a significantly lower risk for inpatient admission (odds ratio, 0.716; 95% CI, 0.539-0.952; P = .02) compared with G+G combinations. Patients with different-MOA SC combinations had significantly lower risks for emergency department visits (odds ratio, 0.853; 95% CI, 0.742-0.980; P = .03) compared with SC+SC combinations. CONCLUSIONS AND RELEVANCE: The findings suggest that AED combinations with different MOAs have greater effectiveness as measured by treatment persistence and lower risks for hospitalization and emergency department visits. Further research is needed to more fully understand the role of the MOA in achieving optimal outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911669     DOI: 10.1001/jamaneurol.2014.808

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  15 in total

1.  Seeking the Rational (or at least avoiding the irrational).

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2015 Sep-Oct       Impact factor: 7.500

Review 2.  Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.

Authors:  Martin J Brodie
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

3.  Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort.

Authors:  Kelly G Knupp; Erin Leister; Jason Coryell; Katherine C Nickels; Nicole Ryan; Elizabeth Juarez-Colunga; William D Gaillard; John R Mytinger; Anne T Berg; John Millichap; Douglas R Nordli; Sucheta Joshi; Renée A Shellhaas; Tobias Loddenkemper; Dennis Dlugos; Elaine Wirrell; Joseph Sullivan; Adam L Hartman; Eric H Kossoff; Zachary M Grinspan; Lorie Hamikawa
Journal:  Epilepsia       Date:  2016-09-12       Impact factor: 5.864

Review 4.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

Review 5.  Selecting Rational Drug Combinations in Epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

6.  Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study.

Authors:  Edward Chia-Cheng Lai; Cheng-Yang Hsieh; Chien-Chou Su; Yea-Huei Kao Yang; Chin-Wei Huang; Swu-Jane Lin; Soko Setoguchi
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

7.  Anti-Epileptic Drug Combination Efficacy in an In Vitro Seizure Model - Phenytoin and Valproate, Lamotrigine and Valproate.

Authors:  Kim Det Taing; Terence J O'Brien; David A Williams; Chris R French
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

Review 8.  Causal inference as an emerging statistical approach in neurology: an example for epilepsy in the elderly.

Authors:  Lidia Mvr Moura; M Brandon Westover; David Kwasnik; Andrew J Cole; John Hsu
Journal:  Clin Epidemiol       Date:  2016-12-30       Impact factor: 4.790

9.  Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment.

Authors:  Rafael Wabl; Samuel W Terman; Maria Kwok; Jordan Elm; James Chamberlain; Robert Silbergleit; Chloe E Hill
Journal:  Neurology       Date:  2021-06-29       Impact factor: 11.800

10.  CRISPR/Cas9 facilitates investigation of neural circuit disease using human iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation.

Authors:  J Liu; C Gao; W Chen; W Ma; X Li; Y Shi; H Zhang; L Zhang; Y Long; H Xu; X Guo; S Deng; X Yan; D Yu; G Pan; Y Chen; L Lai; W Liao; Z Li
Journal:  Transl Psychiatry       Date:  2016-01-05       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.